Glibenclamide/Pioglitazone

Type 2 diabetes (component medicines)

Glibenclamide (glyburide) and pioglitazone are each individually used for type 2 diabetes. A specific FDA-, EMC-, TGA-, or Health-Canada-approved indication statement for a combined glibenclamide/pioglitazone product was not established from the sources reviewed for this draft. (1)

Low blood sugar (hypoglycaemia) — from the glibenclamide component

What to notice: Shakiness, sweating, hunger, a fast heartbeat, confusion, or feeling faint. Hypoglycaemia is listed first among the adverse reactions in the FDA glyburide (glibenclamide) label.

What to do: Treat symptoms with fast-acting sugar and tell the prescriber. Severe hypoglycaemia is a medical emergency — see the serious warnings below. (1)

Stomach upset — from the glibenclamide component

What to notice: Nausea, a full feeling in the upper abdomen, and heartburn. These were the most common reactions in the glyburide clinical trials, occurring in 1.8% of treated patients.

What to do: The FDA label notes these tend to be dose-related and may settle when the dose is reduced. Tell the prescriber if they persist — do not change the dose yourself. (1)

Skin reactions — from the glibenclamide component

What to notice: Itching, redness, hives, or a measles-like or blotchy rash. These occurred in 1.5% of patients in the glyburide clinical trials.

What to do: The FDA label notes these may be temporary and may fade despite continued use, but the drug should be stopped if the skin reaction persists — contact the prescriber. (1)

Fluid retention and swelling (oedema) — from the pioglitazone component

What to notice: Puffy ankles or legs, or breathlessness. The ACTOS label states that fluid retention may occur in a dose-related way and can exacerbate or lead to congestive heart failure.

What to do: Report new or worsening swelling or breathlessness to the prescriber promptly — this is also covered by the boxed warning in the serious warnings below.

Weight gain — from the pioglitazone component

What to notice: The ACTOS label records dose-related weight gain when pioglitazone is used alone or with other antidiabetic medicines. Some of the gain can be fluid rather than fat.

What to do: Weigh yourself regularly as advised and tell the prescriber about rapid weight gain, which can be a sign of fluid retention rather than of eating more.

Broken bones (fractures) — from the pioglitazone component

What to notice: The ACTOS label records an increased incidence of fractures, seen in female patients.

What to do: The label advises applying the current standards of care for assessing and maintaining bone health. Raise bone health with the prescriber, particularly for women taking this medicine long term.

Infections and aches — from the pioglitazone component

What to notice: The most common adverse reactions in the ACTOS label (occurring in 5% or more of patients) are upper respiratory tract infection, headache, sinusitis, muscle pain, and sore throat.

What to do: These are usually mild. Discuss persistent or troublesome symptoms with the prescriber or pharmacist.

Hypoglycemia (low blood sugar) — sulfonylurea class risk

What to notice: Symptoms of low blood sugar; severe hypoglycemia can lead to unconsciousness or convulsions.

What to do: This is a known, sometimes severe risk of the sulfonylurea class that includes glibenclamide/glyburide, particularly in elderly patients and those with kidney impairment. No adverse-reaction incidence/frequency data for this combination was established from the sources reviewed, so this is not presented as a common/expected-frequency effect. Seek urgent medical attention for any severe or persistent symptoms, and discuss individual risk with your prescriber. (1)

Heart failure risk — thiazolidinedione class risk

What to notice: Rapid weight gain, difficulty breathing, or swelling (edema).

What to do: Thiazolidinediones including pioglitazone can cause or worsen congestive heart failure. No adverse-reaction incidence/frequency data for this combination was established from the sources reviewed, so this is not presented as a common/expected-frequency effect. Report these symptoms to your prescriber promptly; this is class-level context from a verified pioglitazone-combination label, not confirmed data for a glibenclamide/pioglitazone product specifically. (2)

Congestive heart failure (thiazolidinedione class boxed warning) — boxed_warning_class_level

Symptoms: Rapid weight gain, difficulty breathing, or swelling.

Action: Seek prompt medical attention for these symptoms. This warning is drawn from a verified FDA label for a different pioglitazone-containing combination (pioglitazone/glimepiride), which carries a boxed warning for this risk and is contraindicated in established NYHA Class III or IV heart failure; it is provided as class-level background, not confirmed data for a glibenclamide/pioglitazone product. (2)

Severe hypoglycemia (sulfonylurea class warning) — emergency

Symptoms: Confusion, sweating, shaking, loss of consciousness, or convulsions.

Action: Severe hypoglycemia is a medical emergency — seek immediate medical help. This is a known risk of the sulfonylurea class that includes glibenclamide/glyburide. (1)

Cardiovascular mortality caution (sulfonylurea class labeling, UGDP study) — boxed_warning_class_level

Symptoms: No specific symptom to watch for — this is a labeling caution about long-term cardiovascular risk, not an acute warning sign.

Action: Discuss your personal cardiovascular risk with your prescriber before starting or continuing a sulfonylurea-class medicine such as glibenclamide/glyburide. The University Group Diabetes Program (UGDP) study reported an association between oral sulfonylurea-class medicines and increased cardiovascular mortality compared with diet alone or diet plus insulin; although only tolbutamide was directly studied, product labeling states it is prudent to consider this warning may apply to other sulfonylureas, including glibenclamide, given their similar mode of action and chemical structure. This is sulfonylurea class-level labeling background, not verified glibenclamide/pioglitazone combination-specific data. (1)

Heart failure

Pioglitazone-containing medicines carry a boxed warning for causing or worsening congestive heart failure and are contraindicated in established NYHA Class III or IV heart failure, per a verified label for a different pioglitazone combination. Tell your prescriber about any history of heart failure. (2)

Kidney impairment and elderly patients

Sulfonylureas such as glibenclamide/glyburide carry a significant hypoglycemia risk, with special caution needed in elderly patients and those with kidney impairment. (1)

Pregnancy and breastfeeding

No pregnancy or breastfeeding data specific to a glibenclamide/pioglitazone product were established from the sources reviewed for this draft.